Michael A. Panzara - 24 Apr 2026 Form 4 Insider Report for IMMUNIC, INC. (IMUX)

Reporting relationship: Chief Medical Officer
Issuer ticker: IMUX
Reported as of: 24 Apr 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 29 Apr 2026, 07:14:41 UTC
Prior SEC filing: 13 Apr 2026
Next SEC filing: 24 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Grant Levine, attorney-in-fact

Key filing fact

Michael A. Panzara filed Form 4 for IMMUNIC, INC. (IMUX) on 29 Apr 2026.

Key facts

This page summarizes Michael A. Panzara's Form 4 filing for IMMUNIC, INC. (IMUX).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 29 Apr 2026, 07:14.

Change

Previous filing in this sequence was filed on 13 Apr 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001679039 Primary reporting owner

Panzara Michael A.

Relationship: Chief Medical Officer
Address: 1200 AVENUE OF THE AMERICAS, SUITE 200, NEW YORK
Signature: /s/ Grant Levine, attorney-in-fact
Signature date: 28 Apr 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

IMUX transaction Derivative

Stock Option

Award

Transaction value
Shares: +300,000
Change %
Price: $0.000000^*
Shares after: 300,000
Date: 24 Apr 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 300,000
Exercise price: $8.80
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The options disclosed on this Form 4 are time vested; 50 percent of the shares underlying the options awarded to the Reporting Person will vest on April 24, 2027, and 50 percent of them will vest in 24 equal monthly installments, subject to the Reporting Person remaining an employee of Immunic, Inc. in good standing through the relevant vesting date.